In the Claims:

Please cancel Claims 2 and 36-44, and amend Claims 1, 5-11, 13, 14, 27, 31, 32, and 34 as follows:

1. (Currently amended) A compound according to the formula (I)



(I)

wherein Z is selected from the group consisting of $-S(O)_2-$ and -C(O)-,

when Z is $-S(O)_2-$, R_a is selected from the group consisting of: -R1 and -N(R1)(R3),

or

when Z is -C(O)-, R_a is selected from the group consisting of: -R1, -OR1, -N(R1)(R3) and -SR1,

where R1 is selected from the group consisting of:

$-C_1-C_{11}$ alkyl, wherein each carbon may be optionally substituted with one, two or three X substituents,

$-C_3-C_{10}$ cycloalkyl, wherein each carbon may be optionally substituted with one or two X substituents,

$-(CH_2)_nQ_p(CH_2)_nW$, and

$-(CH_2)_nCHW_2$;

wherein each carbon of $-(CH_2)_n-$ may be optionally substituted with one or two X substituents, Q is O, S, or NR3, n is independently an integer 0-6, p is independently an integer 0 or 1, and W is independently selected from the group consisting of hydrogen, C_3-C_{10} cycloalkyl, -(C_3-C_{10} cycloalkyl)-aromatic, and one of the following aromatic or heteroaromatic rings:



where B is selected from the group consisting of: -O-, -S-, -NR6-; where each carbon of the aromatic or heteroaromatic ring may be independently substituted by a nitrogen atom, and each carbon of the aromatic ring may be independently substituted with an X substituent;

~~and $-(CH_2)_nCHW_2$;~~

where each X substituent is independently selected from the group consisting of: hydrogen, halogen, methylenedioxy, -C_1-C_8 alkyl, -C_3-C_{10} cycloalkyl, substituted or unsubstituted phenyl, -C_1-C_8 alkoxy, -SR3, -OH, =O, -CY_3, -OCY_3, -CO_2R3, -CN, -CO-NR4R5, -NO_2, -COR3, -NR4R5, -NH-C(O)-R3, -NH-C(O)-(C_1-C_6 alkyl)-aromatic, and -NH-C(O)-(C_1-C_6 alkyl)-heteroaromatic;

where each Y is independently selected from the group consisting of hydrogen and halogen;

where each R3 is independently selected from the group consisting of hydrogen, and C_1-C_8 alkyl, where C_1-C_8 alkyl may be straight or branched, saturated or unsaturated;

where each R4 and R5 is independently selected from the group consisting of hydrogen, and C_1-C_6 alkyl, where C_1-C_6 alkyl may be straight or branched, saturated or unsaturated, where which each carbon of C_1-C_6 alkyl is optionally substituted with an X substituent, or where R4 and R5 taken together with the nitrogen to which they are attached, form a heterocyclic ring of three to seven atoms including the nitrogen atom;

where -NR6- is selected from the group consisting of an unsubstituted N, an N substituted with -hydrogen, -(C_1-C_6 alkyl), -C_3-C_{10} cycloalkyl, -$S(O)_2$-(C_1-C_6 alkyl), -$S(O)_2$-(C_3-C_{10} cycloalkyl), -C(O)R3, -C(O)-(C_0-C_6 alkyl)-aromatic,

and -$S(O)_2$-(C_0-C_6 alkyl)-aromatic, wherein each carbon of the aromatic ring may be optionally substituted with an X substituent; and
where phenyl is substituted with one to five substituents independently selected from the group consisting of hydrogen, halogen, methylenedioxy, -C_1-C_8 alkyl, -C_3-C_{10} cycloalkyl, -C_1-C_8 alkoxy, -OH, -CY_3, -OCY_3, -CO_2R3, -CN, -NO_2, -COR3, -NR4R5, -SR3, -CO-NR4R5, and -NH-C(O)-R3; and

R2 is selected from the group consisting of cyclopentyl, cyclopentenyl, and isopropyl;

or a pharmaceutically acceptable salt, optical isomer, solvate or hydrate thereof.

2. (Canceled)

3. (Previously presented) A method of treating a hyperproliferative disorder in a patient by administration of a compound according to claim 1.

4. (Previously presented) The method according to claim 3, wherein the hyperproliferative disorder is a neoplastic disease.

5. (Currently amended) The method according to claim 4, wherein the neoplastic disease is selected from the group consisting of: leukemia, carcinoma, adenocarcinoma, sarcoma, melanoma ~~or~~ and a mixed type of neoplasm.

6. (Currently amended) The method according to claim 5, wherein the leukemia is selected from the group consisting of: acute lymphoblastic leukemia, chronic leukemia, acute myeloblastic leukemia and chronic mylocytic leukemia.

7. (Currently amended) The method according to claim 5, wherein the carcinoma is selected from ~~those of the~~ the group consisting of: cervis carcinoma, breast carcinoma, prostate carcinoma, esophagus carcinoma, stomach carcinoma, small intestines carcinoma, colon carcinoma, ovary carcinoma and lungs carcinoma.

8. (Currently amended) The method according to claim 5, wherein the adenocarcinoma is selected ~~those of the~~ the group consisting of: cervis adenocarcinoma, breast adenocarcinoma, prostate adenocarcinoma, esophagus adenocarcinoma, stomach adenocarcinoma, small intestines adenocarcinoma, colon adenocarcinoma, ovary adenocarcinoma and lungs adenocarcinoma.

9. (Currently amended) The method according to claim 5, wherein the sarcoma is selected from the group consisting of: oesteroma, osteosarcoma, lipoma, lipsarcoma, hemangiomas and hemangiosarcoma.

10. (Currently amended) The method according to claim 5, wherein the melanoma is selected from the group consisting of: amelanotic melanoma and melanotic melanoma.

11. (Currently amended) The method according to claim 5, wherein the mixed type of neoplasm is selected from the group consisting of: carcinosarcoma, lymphoid tissue type, folicullar reticulum, cell sarcoma and Hodgkins Disease.

12. (Previously presented) The method according to claim 3, wherein the hyperproliferative disorder is a non-neoplastic disease.

13. (Currently amended) The method according to claim 12, wherein the non-neoplastic disease is selected from the group consisting of: allograft rejection, restinosis ~~or~~ and an autoimmune disease.

14. (Currently amended) The method according to claim 13, wherein the autoimmune disease is selected from the group consisting of: rheumatoid arthritis, Type 1 diabetes, atherosclerosis, ~~allograft rejection, or~~ and asthma.

15. (Previously presented) A method of preventing apoptosis of cells in a patient by administration of a compound according to claim 1.

16. (Previously presented) The method according to claim 15, wherein the cells are neuronal cells.

17. (Previously presented) The method according to claim 15, wherein apoptosis is induced by antineoplastic agents.

18. (Previously presented) The method according to claim 15, wherein apoptosis is induced by cerebrovascular disease.

19. (Previously presented) The method according to claim 15, wherein apoptosis is induced by stroke or infarction.

20. (Previously presented) A method of protecting method of protecting neuronal cells from apoptosis comprising administering a compound according to claim 1.

21. (Previously presented) A method of protecting neuronal cells from damage induced by antineoplastic agents, comprising administering a compound according to claim 1.

22. (Previously presented) A method of inhibiting cyclin-dependent kinases (CDKs) by administering a compound according to claim 1.

23. (Previously presented) The method according to claim 22, wherein the CDK is selected from the group consisting of CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D.

24. (Previously presented) A compound according to claim 1 of the formula



25. (Previously presented) A compound according to claim 24 wherein Z is -C(O)-.

26. (Previously presented) A compound according to claim 24 wherein Z is $-S(O)_2-$.

27. (Currently amended) A compound according to claim 25 wherein R_a is selected from the group consisting of: -OR1, ~~or~~ and -N(R1)(R3).

28. (Previously presented) A compound according to claim 25 wherein R_a is -SR1.

29. (Previously presented) A compound according to claim 27 wherein R_a is -OR1.

30. (Previously presented) A compound according to claim 27 wherein R_a is -N(R1)(R3).

31. (Currently amended) A compound according to ~~any of claims 1, 24, 25, 26, 27, 28, 29 or 30~~ claim 1 wherein R_2 is cyclopentyl.

32. (Currently amended) A compound according to ~~claims 1 or 24~~ claim 1 wherein R1 is $-(CH_2)_nQ_p(CH_2)_nW$.

33. (Previously presented) A compound according to claim 30 wherein R1 is $-(CH_2)_nQ_p(CH_2)_nW$.

34. (Currently amended) A compound according to claim 33 wherein W is selected from the group consisting of:



, ~~or~~ and ,

where B is -O-, -S-, -NR6-, where each carbon of the aromatic or heteroaromatic ring may be independently substituted by a nitrogen atom, and each carbon of the aromatic ring may be independently substituted with an X substituent.

35. (Previously presented) A compound according to claim 34 wherein W is phenyl, each carbon of which may be independently substituted with an X substituent.

36-44. (Canceled)